| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_56b11188f223710057739fa8dd37776e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4d33e45e5cbd64b8b893bd62ee22a85b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_43a72884e25aaecffebe0942132d704f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_59e54e3a3f6c7939791986a33289f624 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-73
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-21
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-622
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 |
| filingDate |
2019-12-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_527da23a6c03da1a9df2e1b0ec83fc9e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a5c1a8529efc5775f30c6b83ae646e41
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7cfe10a0b11731e8d8b08b0711573c98
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fb50a9512d30d4c4ae7a0ce22d4b459b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_87c51691def68480317e04901f056955
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b14b6f8db02b3fc4e6df3b9f3c99020b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_eb6baa75695d570a8834ff8b2f983c5e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ccd22390638002cb39cb3c9e0f37b012 |
| publicationDate |
2021-10-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-3898699-A1 |
| titleOfInvention |
Methods and compositions for treating cancers by immuno-modulation using antibodies against cathespin-d |
| abstract |
Inventors have generated two human anti-cath-D scFv fragments cloned in the human IgG1 λ format (F1 and E2) that efficiently bind to human and mouse cath-D, even at the acidic pH of the TNBC microenvironment. F1 and E2 accumulated in TNBC MDAMB- 231 tumor xenografts, inhibited tumor growth and improved mice survival without apparent toxicity. Using this xenograft model, they found that the Fc function of F1 was essential for maximal tumor inhibition. Inventors have shown that the anti-cath-D antibody F1 treatment prevented the recruitment of tumor-associated macrophages and myeloid-derived suppressor cells within the tumor, a specific effect associated with a less immunosuppressive tumor microenvironment. Moreover F1 inhibited tumor growth of TNBC patient-derived xenografts (PDXs). This preclinical proof-of-concept study validates the feasibility and efficacy of an immunomodulatory antibody-based strategy against cath-D to treat patients with TNBC. Accordingly, the present invention relates to an anti-cath-D antibody which inhibits the tumor recruitment of immunosuppressive tumor-associated macrophages M2 and myeloid-derived suppressor cells for use in the treatment of cancer. |
| priorityDate |
2018-12-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |